No data to show
XNAS
WGSWW
Market cap3.67bUSD
Sep 17, Last price
0.08USD
1D
-1.08%
1Q
143.62%
IPO
-94.14%
Name
GeneDx Holdings Corp
Chart & Performance
P/E
—
P/S
0.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
29.87%
Rev. gr., 5y
9.26%
Revenues
305m
+50.79%
Net income
-52m
L-70.25%
CFO
-28m
L-84.18%
Profile
CM Life Sciences, Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 305,450 50.79% | 202,566 -13.69% | 234,694 10.60% | |||
Cost of revenue | 325,256 | 394,921 | 685,889 | |||
Unusual Expense (Income) | ||||||
NOPBT | (19,806) | (192,355) | (451,195) | |||
NOPBT Margin | ||||||
Operating Taxes | (343) | (926) | (49,052) | |||
Tax Rate | ||||||
NOPAT | (19,463) | (191,429) | (402,143) | |||
Net income | (52,286) -70.25% | (175,767) -67.98% | (548,980) 123.72% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 46,496 | 143,002 | 200,607 | |||
BB yield | -2.25% | -213.89% | -225.11% | |||
| Debt | ||||||
Debt current | 3,336 | 4,144 | 6,121 | |||
Long-term debt | 177,087 | 182,211 | 132,397 | |||
Deferred revenue | 54,918 | |||||
Other long-term liabilities | 5,519 | 69,653 | 24,018 | |||
Net debt | 38,248 | 55,220 | 13,685 | |||
| Cash flow | ||||||
Cash from operating activities | (28,496) | (180,147) | (319,155) | |||
CAPEX | (5,491) | (5,711) | (14,322) | |||
Cash from investing activities | (30,132) | (43,726) | (141,326) | |||
Cash from financing activities | 44,162 | 186,238 | 197,315 | |||
FCF | (23,892) | (166,523) | (423,709) | |||
| Balance | ||||||
Cash | 141,185 | 130,148 | 123,933 | |||
Long term investments | 990 | 987 | 900 | |||
Excess cash | 126,902 | 121,007 | 113,098 | |||
Stockholders' equity | (1,351,642) | (1,299,761) | (1,124,383) | |||
Invested Capital | 1,718,576 | 1,717,201 | 1,474,490 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 26,891 | 24,312 | 10,237 | |||
Price | 76.86 2,694.91% | 2.75 -68.41% | 8.71 -94.09% | |||
Market cap | 2,066,859 2,991.42% | 66,858 -24.98% | 89,117 -81.51% | |||
EV | 2,105,107 | 122,078 | 102,802 | |||
EBITDA | 2,147 | (156,521) | (391,886) | |||
EV/EBITDA | 980.49 | |||||
Interest | 3,032 | 3,207 | ||||
Interest/NOPBT | ||||||